Type 2 Diabetes
Videos
Overview
Type 2 diabetes is a chronic metabolic disease in which the body does not respond normally to insulin (insulin resistance) and the pancreas gradually cannot produce enough insulin to compensate. Blood sugar rises, and over years, high glucose damages blood vessels and nerves throughout the body. Type 2 diabetes accounts for about 90% to 95% of all diabetes and is closely linked to excess body weight, particularly fat stored around the abdomen and in the liver (American Diabetes Association, Standards of Care in Diabetes, Diabetes Care, 2025).
For decades, type 2 diabetes was considered a relentlessly progressive disease managed with an ever-growing list of medications. That view has changed. Substantial weight loss, whether through intensive dietary programs, modern medications such as GLP-1 receptor agonists and tirzepatide, or metabolic surgery, can dramatically improve blood sugar and, for many patients, put diabetes into remission (Lean et al., DiRECT trial, Lancet, 2018) (Schauer et al., STAMPEDE trial, New England Journal of Medicine, 2017).
Metabolic (bariatric) surgery is now recognized by the American Diabetes Association as a treatment option for type 2 diabetes in appropriate patients with obesity, based on randomized trials showing better glucose control than medication alone (American Diabetes Association, Standards of Care in Diabetes, Diabetes Care, 2025) (Rubino et al., 2nd Diabetes Surgery Summit, Diabetes Care, 2016).
Why Weight Loss Changes Diabetes
Excess fat stored in the liver and pancreas interferes with insulin action and insulin production. Losing a substantial amount of weight reduces this fat, and in many people the liver becomes more sensitive to insulin within weeks and the pancreas recovers some of its function over months. Bariatric surgery adds hormonal effects: operations that route food quickly into the small intestine increase GLP-1 and other gut hormones that stimulate insulin and reduce appetite, which is why blood sugar often improves within days of gastric bypass, before much weight has been lost.
What Does Remission Mean?
Diabetes remission is generally defined as an HbA1c below 6.5% for at least three months after stopping all glucose-lowering medication (American Diabetes Association, Diabetes Care, 2025). Remission is not a cure, because diabetes can return, especially with weight regain, but even several years of remission lower the risk of complications.
Causes
- Insulin resistance: muscle, liver and fat cells respond poorly to insulin, driven largely by excess visceral and liver fat. See insulin resistance.
- Beta-cell dysfunction: insulin-producing cells in the pancreas become exhausted and decline over time.
- Fat in the liver and pancreas: research suggests excess fat in these organs is a key driver, and removing it through weight loss can restore normal function in many people (Lean et al., DiRECT trial, Lancet, 2018).
- Gut hormone changes, including a reduced incretin (GLP-1) effect
- Genetics and family history
- Lifestyle factors: physical inactivity, poor sleep and diets high in refined carbohydrates and sugary drinks
Risk Factors
- Overweight and obesity, the most important modifiable risk factor
- Prediabetes (HbA1c 5.7% to 6.4%); see prediabetes
- Family history of type 2 diabetes
- Age 35 and older
- Hispanic, Black, Asian American, Native American or Pacific Islander background
- History of gestational diabetes or polycystic ovary syndrome
- High blood pressure, high triglycerides or low HDL cholesterol
- Physical inactivity
- Sleep apnea and short sleep
Waist size matters as much as weight. A waist circumference above about 40 inches in men or 35 inches in women signals excess visceral fat and higher diabetes risk, even at a moderate BMI, with lower thresholds for people of Asian descent.
Who It Affects
Type 2 diabetes affects more than one in ten American adults, and many more have prediabetes (American Diabetes Association, Standards of Care in Diabetes, Diabetes Care, 2025). It is increasingly diagnosed in younger adults and adolescents as rates of obesity rise. In South Florida, the higher prevalence among Hispanic and Black communities makes early screening and effective treatment especially important.
Complications
- Heart attack and stroke, the leading causes of death in people with diabetes
- Kidney disease, which can progress to dialysis; see chronic kidney disease
- Eye damage (retinopathy) and vision loss
- Nerve damage (neuropathy), foot ulcers and amputations
- Fatty liver disease and cirrhosis
- Gastroparesis from nerve damage to the stomach
- Erectile dysfunction and infections
- Cognitive decline
Many of these complications develop silently, which is why annual eye exams, urine albumin testing and foot checks are recommended for everyone with diabetes (American Diabetes Association, Diabetes Care, 2025). Improving glucose, blood pressure and cholesterol together greatly reduces the risk.
Symptoms
Many people have no symptoms for years. When symptoms occur, they include:
- Increased thirst and urination
- Fatigue
- Blurred vision
- Slow-healing cuts and frequent infections
- Tingling or numbness in the hands or feet
- Darkened skin on the neck or armpits (acanthosis nigricans), a sign of insulin resistance
- Unintended weight loss when blood sugar is very high
Diagnosis
Diabetes is diagnosed with any of the following, usually confirmed on repeat testing (American Diabetes Association, Standards of Care in Diabetes, Diabetes Care, 2025):
- HbA1c of 6.5% or higher
- Fasting plasma glucose of 126 mg/dL or higher
- Two-hour glucose of 200 mg/dL or higher during an oral glucose tolerance test
- Random glucose of 200 mg/dL or higher with classic symptoms
Additional testing assesses complications and guides treatment: kidney function and urine albumin, lipid profile, eye examination, foot examination, liver tests and, for surgical candidates, C-peptide to estimate remaining insulin production.
Prediabetes Ranges
An HbA1c of 5.7% to 6.4%, fasting glucose of 100 to 125 mg/dL, or a two-hour glucose of 140 to 199 mg/dL indicates prediabetes. This stage is the best time to act, because weight loss and activity at this point can prevent or delay diabetes.
Differential Diagnosis
- Type 1 diabetes and latent autoimmune diabetes in adults (LADA)
- Monogenic diabetes (MODY)
- Diabetes from pancreatic disease, such as chronic pancreatitis
- Medication-induced diabetes, for example from steroids
- Cushing syndrome and other hormonal disorders
Lifestyle Modifications
- Lose weight: in the DiRECT trial, nearly half of participants achieved remission at one year with an intensive weight-management program, and remission was most likely in those who lost 15 kg or more (Lean et al., DiRECT trial, Lancet, 2018).
- Eat whole foods with plenty of vegetables, lean protein and fiber, and limit refined carbohydrates and sugary drinks.
- Exercise: at least 150 minutes per week of moderate activity plus resistance training (American Diabetes Association, Standards of Care in Diabetes, Diabetes Care, 2025).
- Sleep seven to nine hours and treat sleep apnea.
- Stop smoking.
- Monitor glucose as directed, increasingly with continuous glucose monitors.
Practical Eating Strategies
- Build plates around protein and non-starchy vegetables, with a smaller portion of high-fiber carbohydrates.
- Eliminate sugar-sweetened beverages, including juice and sweet coffee drinks.
- Walk after meals, which lowers post-meal glucose.
- Plan meals and snacks to avoid long gaps that lead to overeating.
Treatment Options
Medications
- Metformin, a long-standing first-line medication
- GLP-1 receptor agonists (semaglutide, dulaglutide, liraglutide) and the dual GIP/GLP-1 agonist tirzepatide: lower blood sugar, promote substantial weight loss and, for several agents, reduce cardiovascular events. In SURPASS-2, tirzepatide lowered HbA1c and weight more than semaglutide 1 mg (Frías et al., SURPASS-2 trial, New England Journal of Medicine, 2021). See medical weight loss.
- SGLT2 inhibitors, which also protect the heart and kidneys
- Insulin and other agents as needed
Metabolic Surgery
Randomized trials consistently show that metabolic surgery controls type 2 diabetes better than medication alone. In the STAMPEDE trial, five years after surgery, 29% of gastric bypass patients and 23% of sleeve gastrectomy patients reached the trial goal of an HbA1c of 6.0% or lower, compared with 5% of patients on intensive medical therapy (Schauer et al., STAMPEDE trial, New England Journal of Medicine, 2017). In a 10-year Italian trial, about a third of surgical patients remained in remission with far fewer complications than medically treated patients (Mingrone et al., Lancet, 2021). Pooled long-term results from four U.S. trials confirmed better glucose control after surgery at seven years and beyond (Courcoulas et al., ARMMS-T2D, JAMA, 2024).
- Gastric bypass is often preferred for diabetes because of its strong hormonal effects. See gastric bypass.
- Sleeve gastrectomy is effective, though remission rates are somewhat lower.
- Duodenal switch and SADI-S produce the highest remission rates, with greater nutritional demands. See SADI-S.
Guidelines support metabolic surgery for people with type 2 diabetes and a BMI of 35 or higher, and consideration at a BMI of 30 to 34.9 when glucose is not controlled with medication, with lower thresholds for people of Asian descent (Rubino et al., 2nd Diabetes Surgery Summit, Diabetes Care, 2016) (American Diabetes Association, Standards of Care in Diabetes, Diabetes Care, 2025).
Who Is Most Likely to Achieve Remission After Surgery?
Remission rates are highest in patients who have had diabetes for a shorter time, do not yet require insulin, have good remaining insulin production (measured by C-peptide) and lose the most weight. Several scoring systems combine these factors to estimate a patient's chance of remission and help choose between operations (Schauer et al., New England Journal of Medicine, 2017). Even patients unlikely to achieve full remission usually need far fewer medications after surgery.
Medications After Surgery
Some patients who do not achieve or maintain remission after surgery benefit from adding a GLP-1 medication or tirzepatide, which can further improve glucose and weight. Combining surgery and medication is now a common, effective strategy.
For a look at the oral and next-generation medications now being studied, read The Future of GLP-1 Medications: Pills, Triple Agonists, and What's Coming Next.
When to See a Doctor
Get screened if you are 35 or older, have overweight or obesity, have a family history of diabetes, or had gestational diabetes. See a doctor promptly for excessive thirst, frequent urination, blurred vision or numbness in the feet.
If you already have diabetes and are taking several medications or insulin without reaching your goals, or are struggling with weight gain from your treatment, it is worth discussing whether medical weight loss or metabolic surgery could help.
When to Seek Treatment
Seek emergency care for very high blood sugar with vomiting, confusion, rapid breathing or extreme thirst, or for very low blood sugar with confusion or loss of consciousness. Seek prompt care for a foot wound that is not healing.
Long-Term Outlook
Even when diabetes returns years after remission, periods of excellent control reduce the risk of complications. Patients who maintain weight loss, stay active and continue follow-up have the best long-term health.
Related Reading and Videos
Read more in our articles GLP-1 Medications vs. Bariatric Surgery: Which One Is Actually Better? The Complete Evidence-Based Comparison and Diabetes Remission After Bariatric Surgery: A Complete Patient Guide. Watch Am I a Candidate for Weight-Loss Surgery? What Qualifies You and Diabetes Gone in DAYS: The Surgery Data Your Doctor Never Told You on our video library. Related conditions include Metabolic Dysfunction–Associated Steatohepatitis (MASH). Treatments that may be involved include Gastric Bypass (RYGB), SADI-S (Single-Anastomosis DuodenoIleal Bypass With Sleeve) and Medical Weight Loss Program.
Prognosis
With modern treatment, people with type 2 diabetes can live long, healthy lives. Outcomes are best when blood sugar, blood pressure and cholesterol are controlled together. Remission is most likely when substantial weight loss occurs early in the course of the disease, before the pancreas has lost much of its insulin-producing capacity (Lean et al., DiRECT trial, Lancet, 2018).
Why Choose Dr. de la Cruz-Muñoz
Type 2 diabetes is one of the most powerful reasons to treat obesity. Dr. de la Cruz-Muñoz is a board-certified metabolic and bariatric surgeon who has helped thousands of patients improve or resolve diabetes. His practice offers the full range of options, from GLP-1 and other medications through a medical weight-loss program to gastric bypass, sleeve gastrectomy, SADI-S and duodenal switch, with each patient matched to the approach most likely to control their diabetes for the long term.
Dr. de la Cruz-Muñoz has published long-term research showing that bariatric surgery significantly decreased the prevalence of type 2 diabetes and prediabetes among multiethnic adults (de la Cruz-Muñoz et al., Journal of the American College of Surgeons, 2011), as well as studies on predictors of diabetes remission after gastric bypass (Iacobellis et al., Obesity Surgery, 2015).
Dr. de la Cruz-Muñoz has been performing bariatric surgery for over 25 years and has completed more than 9,000 bariatric operations — a volume few surgeons reach.
Featured Procedures
.png)
FAQ
Early results are promising. MagDI combines a sleeve gastrectomy with a magnet-created duodeno-ileal connection, similar in concept to SADI-S, which is known for strong diabetes improvement. Bringing food to the lower intestine sooner increases GLP-1 and improves insulin sensitivity, and early studies report substantial improvements in blood sugar and reductions in diabetes medications. Because MagDI is a newer procedure, long-term data are still being collected.
Gastric bypass is a very powerful bariatric procedure for diabetes improvement. Many patients experience immediate normalization of blood sugar within days due to hormonal changes, even before significant weight loss occurs. While not every patient achieves full remission, most see dramatic reductions in medications, improved A1c, and long‑term metabolic stability.
Yes. Both produce larger reductions in diabetes risk than lifestyle changes alone, but the benefit of medication lasts only while it's taken.
- Tirzepatide (Zepbound): In the 3-year SURMOUNT-1 trial (https://doi.org/10.1056/NEJMoa2410819) of adults with obesity and prediabetes, only 1.3% of people on tirzepatide developed type 2 diabetes, compared with 13.3% on placebo, about a 94% risk reduction (Jastreboff et al., New England Journal of Medicine, 2025).
- Semaglutide (Wegovy): In the STEP 1 trial, 84% of participants with prediabetes returned to normal blood sugar after 68 weeks, compared with 48% on placebo (Perreault et al., Diabetes Care, 2022). After semaglutide was stopped, many slipped back into the prediabetes range as weight returned (Wilding et al., Diabetes, Obesity and Metabolism, 2022).
- Bariatric surgery: In the Swedish Obese Subjects study (https://doi.org/10.1056/NEJMoa1112082), surgery reduced the long-term risk of type 2 diabetes by 78% over 15 years. In people with impaired fasting glucose (one form of prediabetes), the reduction was 87% (Carlsson et al., New England Journal of Medicine, 2012). In that group, about 1.3 patients needed surgery to prevent one case of diabetes over 10 years (Sjöström, Journal of Internal Medicine, 2013).
No medication is FDA-approved specifically to prevent diabetes (Echouffo-Tcheugui et al., JAMA, 2023). These treatments are used for patients who also have obesity, and the right choice depends on BMI, other health conditions, and long-term goals.
Prediabetes can often be reversed, and type 2 diabetes is not inevitable. Without treatment, about 10% of people with prediabetes in the U.S. develop diabetes each year (Echouffo-Tcheugui et al., JAMA, 2023). In the China Da Qing study, almost 96% of untreated participants eventually developed diabetes over 30 years (Echouffo-Tcheugui et al., JAMA, 2023).
The good news is that modest, sustained weight loss changes that path. In the landmark Diabetes Prevention Program trial (https://doi.org/10.1056/NEJMoa012512), losing at least 7% of body weight and getting 150 minutes of moderate activity per week, such as brisk walking, cut the risk of developing type 2 diabetes by 58% over 3 years. The benefit lasted for decades: risk was still 24% lower at 21 years (American Diabetes Association, Standards of Care in Diabetes, 2026). Weight loss of 7% to 10% is the threshold most strongly linked to prevention (American Association of Clinical Endocrinology, 2026). Metformin lowered risk by 31% and works best in younger adults, people with a BMI of 35 or higher, and women with prior gestational diabetes (National Institute of Diabetes and Digestive and Kidney Diseases, 2018).
For eligible patients, yes. Living with untreated severe obesity carries substantially higher long-term risk than surgery. Bariatric surgery lowers all-cause mortality by 30–50% and is linked to a median life expectancy roughly 6 years longer than usual care, along with large reductions in diabetes, hypertension, and cardiovascular death (Syn et al., Lancet, 2021; Wiggins et al., PLoS Medicine, 2020). The risk of not operating often exceeds the risk of surgery.
Yes. Remission means normal blood sugar levels without diabetes medications. In the DiRECT trial, nearly half of patients who followed an intensive weight-management program achieved remission at one year (Lean et al., Lancet, 2018). Bariatric and metabolic surgery produce higher and more durable remission rates than medical therapy alone, as shown in the STAMPEDE trial (Schauer et al., New England Journal of Medicine, 2017). Remission is most likely when diabetes has been present for fewer years and before insulin is needed. Patients in remission still need regular monitoring because diabetes can return.
It depends on your treatment. People using insulin, especially multiple daily injections, usually check several times a day or use a continuous glucose monitor. Those on medications that can cause low blood sugar, such as sulfonylureas, may check once or twice a day, while people managing type 2 diabetes with diet or metformin may need less frequent checks plus regular A1C tests. After bariatric surgery, blood sugar can drop quickly, so more frequent monitoring is needed while medications are adjusted.
Type 1 diabetes is an autoimmune disease in which the immune system destroys the insulin-producing cells of the pancreas, so the body makes little or no insulin and insulin treatment is always required. Type 2 diabetes is driven mainly by insulin resistance — often linked to excess abdominal fat — combined with a gradual decline in insulin production. Type 2 is far more common, can sometimes be put into remission with significant weight loss or metabolic surgery, and is treated with lifestyle changes, medications and sometimes insulin.
Not necessarily. What matters most is the overall quality of your diet, portion sizes and how carbohydrates affect your blood sugar. Limiting added sugars, sweetened drinks and refined starches helps, while fiber-rich foods, vegetables, lean protein and healthy fats keep blood sugar steadier. Small amounts of sweets can fit into a balanced plan. After bariatric surgery, sugary foods can also trigger dumping syndrome, so they are best avoided.
There is no cure for type 1 diabetes. Type 2 diabetes can often be put into remission — normal blood sugar without medication — especially with substantial weight loss. Metabolic surgery produces the highest and most durable remission rates, as shown in randomized trials (Schauer et al., New England Journal of Medicine, 2017), and intensive diet programs can also achieve remission in some patients (Lean et al., Lancet, 2018). Remission is most likely early in the disease, and ongoing monitoring is needed because diabetes can return.
Yes. The duodenal switch has the highest rates of type 2 diabetes remission of any bariatric operation, thanks to substantial weight loss, reduced absorption and strong gut hormone changes. It is particularly considered for patients with severe obesity and advanced diabetes. The trade-off is a greater need for lifelong nutritional monitoring.
Yes. Both medical and surgical obesity treatments improve blood sugar control and insulin resistance. Losing 5–10% of body weight measurably lowers A1C, GLP-1 medications improve diabetes directly as well as through weight loss, and metabolic surgery produces the largest effect, often leading to remission (Schauer et al., New England Journal of Medicine, 2017). Diabetes medications usually need to be reduced as treatment works, so close monitoring is important.
Yes. Metabolic surgery is one of the most effective treatments for type 2 diabetes, often leading to remission or major reductions in medication. Randomized trials have shown better blood sugar control with surgery than with intensive medical therapy alone (Schauer et al., New England Journal of Medicine, 2017). Gastric bypass, SADI-S and duodenal switch have the strongest effects. Benefits are greatest when surgery is done earlier in the course of diabetes.
Choosing an experienced program matters for metabolic surgery because the most powerful operations — gastric bypass, SADI-S, MagDI and duodenal switch — require surgical expertise and long-term nutritional follow-up. The Miami program offers the full range of metabolic procedures, care focused on diabetes and fatty liver outcomes, and virtual follow-up for patients who travel. Dr. de la Cruz-Muñoz has performed more than 9,000 bariatric operations over more than 25 years — a volume few surgeons reach.
Metabolic surgery uses bariatric operations to treat metabolic diseases such as type 2 diabetes, fatty liver, high blood pressure and high cholesterol, not just excess weight. By changing gut hormones, insulin sensitivity and how nutrients are absorbed, procedures such as gastric bypass, SADI-S and duodenal switch can put diabetes into remission and reduce cardiovascular risk. Current guidelines support metabolic surgery for people with a BMI of 30–34.9 who have metabolic disease (Eisenberg et al., Surgery for Obesity and Related Diseases, 2022).
Yes. Modern metabolic surgery is one of the safest elective operations performed today, with a risk of death of about 0.1 percent, comparable to common operations such as gallbladder surgery, appendectomy and joint replacement (American Society for Metabolic and Bariatric Surgery, Metabolic and Bariatric Surgery Fact Sheet, 2025).
Serious complications are uncommon, especially at accredited centers with experienced surgeons. Research also shows that patients who have metabolic surgery live longer than similar patients who do not.
.webp)
.webp)
